CareDx (NASDAQ:CDNA) Downgraded by Wall Street Zen to Buy

Posted by Brenda Bartman on Oct 31st, 2026

CareDx (NASDAQ:CDNA – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report released on Saturday, Wall Street Zen reports.

Several other brokerages have also issued reports on CDNA. Canaccord Genuity Group set a $99.00 price target on CareDx in a research note on Friday. Craig Hallum upgraded CareDx from a “hold” rating to a “buy” rating and set a $64.00 price objective for the company in a research report on Monday, August 3rd. BTIG Research boosted their price objective on CareDx from $81.00 to $92.00 and gave the stock a “buy” rating in a report on Friday. Zacks Research cut CareDx from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. Finally, HC Wainwright restated a “neutral” rating and set a $46.00 target price on shares of CareDx in a research report on Friday, July 31st. Three equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $64.40.

Read Our Latest Report on CDNA

CareDx Price Performance

CDNA stock opened at $87.41 on Friday. The company has a 50 day moving average price of $59.93 and a 200 day moving average price of $33.63. CareDx has a fifty-two week low of $14.27 and a fifty-two week high of $90.87. The stock has a market capitalization of $4.52 billion, a PE ratio of 108.36 and a beta of 2.38.

CareDx (NASDAQ:CDNA – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.25 by $0.45. The firm had revenue of $139.36 million for the quarter, compared to analyst estimates of $121.96 million. CareDx had a return on equity of 10.58% and a net margin of 25.86%. The business’s quarterly revenue was up 39.3% compared to the same quarter last year. During the same period last year, the company earned $0.03 EPS. As a group, equities analysts expect that CareDx will post 0.47 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other CareDx news, Director George Bickerstaff, III sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $46.28, for a total transaction of $925,600.00. Following the transaction, the director owned 134,061 shares in the company, valued at approximately $6,204,343.08. This trade represents a 12.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christine Cournoyer sold 16,000 shares of the business’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $46.94, for a total value of $751,040.00. Following the transaction, the director owned 42,943 shares of the company’s stock, valued at $2,015,744.42. The trade was a 27.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CDNA. BlackRock Inc. acquired a new position in CareDx during the second quarter valued at approximately $137,219,000. Bamco Inc. NY bought a new stake in CareDx in the second quarter valued at approximately $55,214,000. Amova Asset Management Americas Inc. raised its holdings in CareDx by 2.0% in the first quarter. Amova Asset Management Americas Inc. now owns 1,475,126 shares of the company’s stock worth $25,608,000 after purchasing an additional 28,510 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its holdings in CareDx by 2.0% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,475,126 shares of the company’s stock worth $25,608,000 after purchasing an additional 28,510 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in shares of CareDx by 11.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,461,914 shares of the company’s stock valued at $25,375,000 after buying an additional 151,934 shares during the period.

CareDx Company Profile

(Get Free Report)

CareDx, Inc is a healthcare diagnostics company focused on improving the care of organ-transplant patients. The company develops and commercializes noninvasive tests and digital tools intended to help physicians assess transplant-organ health, identify potential rejection, and support long-term patient management.

Its offerings include AlloSure donor-derived cell-free DNA tests for monitoring transplant recipients, AlloMap gene-expression testing for heart-transplant patients, and HeartCare, which combines AlloMap and AlloSure results.